A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product.
作者信息
Zheng Si-Li, Zhang Xiao-Qing
机构信息
Department of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
出版信息
Int J Health Policy Manag. 2024;13:8543. doi: 10.34172/ijhpm.8543. Epub 2024 Aug 20.
Abstract
摘要
相似文献
1
A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product.一家中国公司推出基于结果的新型支付计划，以提高患者对CAR-T产品的可承受性。
Int J Health Policy Manag. 2024;13:8543. doi: 10.34172/ijhpm.8543. Epub 2024 Aug 20.
2
Value and affordability of CAR T-cell therapy in the United States.美国嵌合抗原受体T细胞疗法的价值与可及性
Bone Marrow Transplant. 2020 Sep;55(9):1706-1715. doi: 10.1038/s41409-020-0956-8. Epub 2020 May 30.
3
CAR-T cell therapies: patient access and affordability solutions.嵌合抗原受体T细胞疗法：患者可及性与可负担性解决方案
Future Sci OA. 2025 Dec;11(1):2483613. doi: 10.1080/20565623.2025.2483613. Epub 2025 Mar 29.
4
Individual market health plan affordability after cost-sharing reduction subsidy cuts.个户医保计划在自付减免补贴削减后的负担能力。
Health Serv Res. 2019 Aug;54(4):730-738. doi: 10.1111/1475-6773.13190. Epub 2019 Jun 20.
5
Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells.从快速眼动睡眠中苏醒：美国血液与骨髓移植学会关于嵌合抗原受体T细胞安全使用的持续80/20建议
Transplant Cell Ther. 2025 Jun;31(6):349.e1-349.e12. doi: 10.1016/j.jtct.2025.02.009. Epub 2025 Feb 13.
6
Paying For Value From Costly Medical Technologies: A Framework For Applying Value-Based Payment Reforms.为昂贵的医疗技术的价值付费：应用基于价值的支付改革的框架。
Health Aff (Millwood). 2020 Jun;39(6):1018-1025. doi: 10.1377/hlthaff.2019.00771.
7
Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application.土耳其学术 CAR-T（ISIKOK-19）细胞临床试验初步报告：产品特征及临床应用结果。
Turk J Haematol. 2022 Aug 25;39(3):206-210. doi: 10.4274/tjh.galenos.2022.2022.0193. Epub 2022 Jul 18.
8
Implementation of a CAR-T cell therapy program in India.在印度实施嵌合抗原受体T细胞（CAR-T）疗法项目。
Expert Rev Anticancer Ther. 2025 Jun;25(6):599-608. doi: 10.1080/14737140.2025.2501744. Epub 2025 May 8.
9
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.儿童和青少年癌症嵌合抗原受体T细胞药物开发儿科战略论坛：ACCELERATE与欧洲药品管理局合作，并由美国食品药品监督管理局参与。
Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.
10
Amoxicillin pulsatile - MiddleBrook: APC 111, APC-111, PULSYS-enhanced amoxicillin.阿莫西林脉冲制剂 - 米德尔布鲁克：APC 111、APC - 111、PULSYS增强型阿莫西林。
Drugs R D. 2007;8(6):395-9. doi: 10.2165/00126839-200708060-00007.
引用本文的文献
1
Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.嵌合抗原受体工程化细胞免疫疗法的当前挑战与新出现的机遇
Exp Hematol Oncol. 2025 Jul 2;14(1):92. doi: 10.1186/s40164-025-00683-y.
本文引用的文献
1
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.嵌合抗原受体自然杀伤（CAR-NK）细胞疗法的进展：从嵌合抗原受体 T（CAR-T）细胞疗法中吸取的经验教训。
Front Immunol. 2023 May 2;14:1166038. doi: 10.3389/fimmu.2023.1166038. eCollection 2023.
2
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.优化血液系统恶性肿瘤嵌合抗原受体 T 细胞治疗的策略：中国经验。
Haematologica. 2023 Aug 1;108(8):2011-2028. doi: 10.3324/haematol.2022.282316.
3
China enters CAR-T cell therapy era.中国进入嵌合抗原受体T细胞免疫疗法时代。
Innovation (Camb). 2021 Dec 16;3(1):100197. doi: 10.1016/j.xinn.2021.100197. eCollection 2022 Jan 25.
4
The use of innovative payment mechanisms for gene therapies in Europe and the USA.在欧洲和美国，基因疗法采用创新的支付机制。
Regen Med. 2021 Apr;16(4):405-422. doi: 10.2217/rme-2020-0169. Epub 2021 Apr 13.
5
Value and affordability of CAR T-cell therapy in the United States.美国嵌合抗原受体T细胞疗法的价值与可及性
Bone Marrow Transplant. 2020 Sep;55(9):1706-1715. doi: 10.1038/s41409-020-0956-8. Epub 2020 May 30.
6
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.基因疗法基于结果的实际报销情况：欧洲主要国家近期推出的嵌合抗原受体T细胞（CAR-T）疗法的经验
J Mark Access Health Policy. 2020 Jan 15;8(1):1715536. doi: 10.1080/20016689.2020.1715536. eCollection 2020.
7
CAR T-cell product performance in haematological malignancies before and after marketing authorisation.上市前后血液恶性肿瘤中嵌合抗原受体 T 细胞产品的性能。
Lancet Oncol. 2020 Feb;21(2):e104-e116. doi: 10.1016/S1470-2045(19)30729-6.
Zotero 插件